HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Senores Pharmaceuticals gets nod to acquire 100% share capital of Apnar Pharma
Dec-16-2025

Senores Pharmaceuticals has received approval for the acquisition of 100% share capital of Apnar Pharma. In this regard, the company has entered into a Share Purchase Agreement (SPA) with Apnar Pharma, is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat.

The said transaction is to be completed in two tranches, first tranche of the transaction to be completed in current fiscal by March 2026 and second tranche is expected to complete by Q2 of FY 2027. Upon consummation of the acquisition shall become a wholly owned subsidiary of the company. The Management Committee of the Board of Directors of the company, in its meeting held on December 15, 2025, has considered and approved the same.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.

  RELATED NEWS >>